1[1]Schellhorn C. Classification of quinolones by V Andriole [J].Infection, 1998, 26(1):64.
2[2]Chu D T W,Fernandes P B.Structure-activity relationships of the fluoroquinolones[J].Antimicrob Agents Chemother, 1989, 33(2):131～135.
3[3]Stahlmann R,Schwabe R.Safety profile of grepafloxacin as compared with fluoroquinolones [J]. J Antimicrob chemother,1997,40(suppl.A):83～92
4[4]Stahlmann R. Safety profile of the quinolones[J].J Antimicrob Chemother, 1990 , 26(Suppb.D):31～44.
5[5]Akahane K, Sekiguchi M,Une T,et al. Structure-epileptogenicity relationships of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites[J].Antimicrob Agents Chemother,1989,33(10):1704～1708.
7[8]Robertson D G,Epling G A,Kiely J S,et al.Mechanistic studies of the photoxic potential of PD 117596,a quinolone antibacterial compound [J].Toxicol Appl Pharmacol,1991,111(2):221～232.
8[9]Giamarellou H,Kilokythas E,Petrikkos G,et al,pharmacokinetics of three newer quinolones in pregnant and lactating women[J].Am J Med,1989,87(suppl.5A):49～51.
9[11]Temafloxacin withdraw from market [J].Market Letter,1993,20(11):23.
10[12]"Wave"of new products from Pfizer[J].Scrip,1994,1971:10～11.
